
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 AND 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of June 2014

File No. 000-54598

Stellar Biotechnologies Inc.

(Name of Registrant)

332 E. Scott Street, Port Hueneme, CA 93041

(Address of Principal executive offices)

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

FORM 20-F

FORM 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

SIGNATURE

Pursuant to the requirements of the securities Exchange Act of 1934, the registrant has duly caused this Form 6-K to be signed on its behalf by the undersigned, thereunto duly authorized.

Stellar Biotechnologies, Inc.
(Registrant)

Dated: 6/24/14

By: /s/ Kathi Niffenegger
Kathi Niffenegger
Chief Financial Officer

Exhibits:

[99.1](#) Stellar Biotech (SBOTF) Corporate Presentation, June 2014

Stellar

BIOTECHNOLOGIES

Powering and Improving Immunotherapy

(OTCQB: SBOTF) (TSX-V: KLH)


Stellar Biotechnologies, Inc. Corporate Presentation

June 2014

A 2014
TSX Venture 50
Company

www.StellarBiotech.com

www.KLHsite.org



Safe Harbor

This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; governmental regulations and the ability or failure to comply with governmental regulations; the timing of anticipated results; and other factors referenced in Stellar's filings with securities regulators. For a discussion of further risks and uncertainties related to our business, please refer to our public company reports filed with the TSX Venture Exchange and the U.S. Securities and Exchange Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, we assume no obligation to update such statements. This presentation does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the information contained in this presentation.

Stellar Biotech: Powering and Improving Immunotherapy™

Unique, World-Leading Technology

- Only company capable of sustainable/scalable and fully traceable supply of the widely-used immune-stimulating protein: **Keyhole Limpet Hemocyanin (KLH)**

Fastest-Growing Biopharma Sector

- Stellar KLH products & technology target **immunotherapy** and immunodiagnostics, biopharma's fastest-growing sectors.

Strong Growth Roadmap

- **Multiple** commercial and clinical pathways.
- New: Strategic expansion with exclusive immunotherapy technology targeting *Clostridium difficile* infection.

Environmental Advantage

- Our **ground-breaking** work revolutionized KLH manufacturing
- Unprecedented standards, competitive edge

A History of Building Value

Stellar BIOTECHNOLOGIES

Powering and Improving Immunotherapy




1999

Founding
Private, U.S.-based
company (Calif.)
Aquaculture facility
\$1M NIH grant
funding




2004

KLH supply
agreements for
cancer vaccines
\$3M NCI grant
funding for
development of
GMP-grade KLH



2005-2009

Patent for KLH
protein extraction
methods (U.S.,
Canada, Europe)
GMP KLH
Vaccine & supply
partnerships



2010-2011

Stellar public on
TSX Venture
Exchange (4/2010)
\$3.1M financing
NSF Phase IIb grant
funding
Diagnostic co-
development
agreement



2012-2013

Exclusive WW C. diff license
Multiple industry firsts in
aquaculture science
Expanded IP (mfg. &
adjuvant technologies, C.
diff immunotherapy)
KLH Site™
FDA master files
\$12M financing
Amaran collaboration

Key Facts & Financials




- Trading Symbols: OTCQB: SBOTF
TSX-V: KLH
- Headquarters: Port Hueneme, CA
- Fiscal Year End: August 31
- Accounting Firm: D & H Group LLP,
Vancouver BC, Canada
- Legal Counsel: Greenberg Traurig LLP


Selected Financials	
Stock Price (5/20/14)	\$1.15
52 – Week Range	\$0.43-\$2.30
Shares Outstanding	78.1M
90-Day Average Trading Volume	212,484
Market Capitalization	\$90M
Debt (2/28/14)	\$0
Cash and Short Term Investments (2/28/14)	\$15.8M
Shareholders Equity (2/28/2014)	\$9.1M
TTM Revenue (2/28/14)	\$518.5K

Stellar Financial Filings: <http://ir.stellarbiotechnologies.com/all-sec-filings>

Keyhole Limpet Hemocyanin



Intricate Topology of KLH
Molecular Structure



- Natural, immune-stimulating protein.
- Sole source is rare marine mollusk.
- 40+ years safe use in clinical immunology.
- Vital in preclinical and clinical research.
- Rapid growth in immunotherapy = High demand.

Robust, Adaptable Platform


- | | |
|----------------------|---|
| • Cancer | • Inflammatory disease (Crohn's, Lupus) |
| • Infectious Disease | • Alzheimer's |
| • Autoimmune (RA) | • Immune Function Testing |

www.KLHsite.org



You Already Know KLH (you just didn't know it)

(1) As an API, KLH transforms tiny haptens into effective immunotherapies....




KLH-Active Immunotherapies

CellDex, Neovacs, Affiris, OBI, Bayer, Peptinov, Scripps, NCI, Genentech, MabVax, Chilka, Biovest, Peptivir, Baylor, Abramson, MSKCC, Stanford

....or (2) as an injectable product, KLH is widely used to measure immune effects of new drugs.

Using KLH in Immunotoxicology

Amgen, Pfizer, Roche, Novartis, Bristol-Myers, Biogen, J&J, NIAID, GSK, Novo Nordisk, Genentech



High Barriers to Entry

- Stellar is only producer WW of sustainable, scalable and fully-traceable GMP-grade KLH
- Pioneering marine biotechnology
 - Only-in-class aquaculture + proprietary KLH production
- IP covering core KLH business + new R&D
- Fiscal strength
 - 8 years R&D funded by \$7M in NIH & NSF grants
 - Plus \$23M in equity funding to date
- Expert management and advisory
 - KLH, immunology, drug commercialization




High Barriers to Entry

5-10 years and \$20+ million investment ahead of any potential competitor

Supply Dynamics Favor Stellar Biotech

- KLH molecule is large and complex; has not been synthesized
- One marine source, one location
- Commercial scale constraints
 - Giant Keyhole Limpet requires 5 years until fully mature
 - Protein-rich hemocyanin can be extracted 3X/year
- 1 gram GMP KLH has commercial value of \$40,000-\$50,000




Stellar KLH™ Products

Molecular structure provides for multiple product configurations.
Stellar KLH™ known for high quality and consistency.




Stellar KLH™
Protein

- KLH protein for Vaccine conjugation
- KLH Protein for TDAR & Immune Function Testing
- KLH custom formulations & services
- Bulk and vial configurations



Stellar KLH™
ELISA Test Kit

Multiple High-Value Pathways



World-Leading Stellar KLH™ Platform

* Ex: C. Diff Vaccine Program

KLH Growing Demand & Market Potential

KLH-Based Active Immunotherapy Trials*

Clinical Status	Indication	Company or Institute
Phase III	Glioblastoma Breast Cancer	Celldex (Rindopepimut) OBI Pharma (OBI-822)
Phase II	Crohn's Disease Lupus Rheumatoid Arthritis Alzheimer's Multiple Myeloma Melanoma Lymphoma Melanoma Ovarian Cancer Sarcoma Leukemia	Neovacs (TNF Kinoid) Neovacs (IFNa Kinoid) Neovacs (TNF Kinoid) Affiris/GSK (AFF002) Abramson Center Baylor Research Clinica Navarra Dermatologische Klinik Loyola University MabVax NCI
Phase I	N-H Lymphoma Brain Tumor Glioblastoma Lung Cancer Neuroblastoma Ovarian Cancer	Bayer (Autologous) Rockefeller Roswell Park Sloan-Kettering Sloan-Kettering Sloan-Kettering

- Not a comprehensive list
- Does not include KLH immunotoxicology use

Major Disease Categories

Cancer
Inflammatory Disease
Immune Disorders
Alzheimer's
Infectious Disease

KLH Market Potential

\$10M to \$200M
per Disease Category

Major Biopharma Use

Celldex, Neovacs, Affiris, OBI,
Bayer, Peptinov, Scripps, NCI,
Genentech, MabVax, Chilka,
Baylor, Biovest, Peptivir,
Abramson, MSKCC, Stanford
Pfizer, Sanofi, Merck, J&J

Strategic Corporate Partner

Stellar
Biotech

Amaran

- Amaran Biotechnology in Taiwan
 - Immunotherapy developer/manufacturer
 - Invested US\$ 5 Million in Stellar's Sep. 2013 financing
- Collaborative agreement signed Dec. 2013 to evaluate and development manufacturing methods for OBI-822 immunotherapy using Stellar KLH™
- OBI-822 Active Immunotherapy breast cancer
 - KLH is key ingredient



- Metastatic Breast Cancer: Phase II/III trials in U.S., Taiwan, South Korea, India, Hong Kong
- Ovarian Cancer: Phase I/II for ovarian cancer in Taiwan

Strategic pathway
to long-term
revenue and
clinical potential
for Stellar KLH™

Stellar Proprietary Immunotherapy

Stellar's Exclusive Immunotherapy Technology Clostridium Difficile Infection (*C. diff*)



- Exclusive WW license to broad patent portfolio
- Game-changing potential
- Technology advantage: Cell-directed therapy
- Positive early preclinical results published
- Secondary preclinical studies completion expected early 2H2014

Major, growing cause of hospital death & morbidity

300,000 new cases, 14,000 deaths annually

Hospital stays from *C. diff* up 3X in last 10 years


C. diff bacteria overgrows due to antibiotic use

Progressive Achievements

- **Major aquaculture science milestones**
 - Ground-breaking industry and environmental firsts
- **Intellectual property expanded**
 - Two patents issued for C. diff technology (U.S. and China)
 - Application for novel KLH combinatorial adjuvant technology
- **New Master File to U.S. FDA CBER**
 - Significance: Expedite customer regulatory processes
- **Peer-review and scientific recognition**
 - Expert Review of Vaccines journal article (C. diff biochemistry)
 - Journal of Immunotoxicology (form and commercial source of KLH matters)
 - ClostPath 8 oral presentation (C. diff preclinical preliminary result)
 - Vaccine Congress poster (C. diff preclinical preliminary result)
 - NSF Conference poster (Aquaculture achievements)

Future Milestones & Catalysts

- New collaborations and supply contracts with biopharma partners
- C. diff immunotherapy program complete preclinical study
- Aquaculture production capacity and expansion
- Prepare for transition to major U.S. stock exchange



Senior Executive Leadership

Frank Oakes President & CEO	<ul style="list-style-type: none">• 35 years experience; biotechnology and aquaculture. Aquaculture industry leader and KLH manufacturing expert. Formerly CEO of Abalone Farms, Inc.; leader through R&D, capitalization and commercialization to become first profitable and largest abalone producer in U.S.
Herbert Chow, Ph.D. Chief Technology Officer	<ul style="list-style-type: none">• 25 years experience; pharmaceutical product development & commercialization in therapeutic and diagnostic markets. Key senior management positions at both start-up biotech and major pharma companies including at Abbott Labs and Johnson & Johnson. Ph.D. Immunology.
Catherine Brisson, Ph.D. Chief Operating Officer	<ul style="list-style-type: none">• 20 years experience; biotech, pharma and medical device industries, including at Sicom Pharmaceuticals (Teva Parenteral Products). Expertise in QA, QC, Regulatory and Manufacturing. Ph.D. Organic Chemistry.
Kathi Niffenegger Chief Financial Officer	<ul style="list-style-type: none">• 30 years experience; accounting and finance, range of industries including pharma. Outside CPA to Stellar since Company founding. Previously partner at Glenn Burdette, CFO at Martin Aviation, Peat Marwick, Mitchell (KPMG LLP).
Mark McPartland VP, Corporate Development & Communications	<ul style="list-style-type: none">• 16 years experience; business development, capital markets advisory, corporate communications. Previously Senior VP at MZ Group, VP and Partner at Alliance Advisors LLP, and Regional VP of Hayden Communications.

Key Points Summary



Industry-leading and unequaled core competency in KLH

Versatile technology platform and products

KLH essential to immunotherapy, fastest-growing biopharma sector

Multiple, high-value commercial pathways

Progressive achievements and collaborations

Environmental champion

Exclusive R&D drives pipeline: C. diff Immunotherapy Program

Fiscal strength = ability to execute

Stellar IP & Proprietary Assets

KLH Manufacture & Aquaculture

- US 6852338 (2005) Non-lethal method for extracting crude hemocyanin from gastropod molluscs
- Patent filings for production methods and adjuvant technologies
- Proprietary methods for control of *M. crenulata* life cycle including culture systems, nutrition, seawater purification
- First-ever industry achievement of multiple generations of source animal within land-based aquaculture
- Commercial-scale aquaculture facility

Clostridium difficile Immunotherapy

- US 8,597,663 (2013) Polysaccharide Immunogens from *Clostridium difficile*
- China CN ZL 200880115518.2 Novel Polysaccharide Immunogens from *Clostridium difficile*
- Japan 5501969 Novel Polysaccharide Immunogens from *Clostridium difficile*

Key Supporting Links

Company Website	www.stellarbiotech.com
Investor Overview	http://ir.stellarbiotechnologies.com/
KLH Knowledge Base	www.KLHsite.org
KLH Definition	http://en.wikipedia.org/wiki/Keyhole_limpet_hemocyanin
Key KLH Immunotherapies in Development*	<ul style="list-style-type: none">• Neovacs: http://neovacs.fr/products/technology/• OBI Pharma: http://www.obipharma.com/index.aspx?lang=eng&fn=pipeline_content&no=3• Celldex: http://www.celldex.com/pipeline/rindopepimut.php• Biovest: http://www.businesswire.com/news/home/20140113005588/en/European-Medicines-Agency-Accepts-Marketing-Authorization-Application#.U1r0PI1OWUk

- Not a comprehensive list

Powering and Improving Immunotherapy with Stellar KLH™

Stellar

BIOTECHNOLOGIES

Powering and Improving Immunotherapy

(OTCQB: SBOTF) (TSX-V: KLH)

Frank R. Oakes

President & CEO

Office +1 (805) 488-2800

IR@stellarbiotech.com

Mark A. McPartland

V.P. Corporate Development

& Communications

Office +1 (805) 488-2800 ext. 103

markmcp@stellarbiotech.com

www.StellarBiotech.com

www.KLHsite.org

